Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains On News Of Additional Positive Results From Phase 3 Paridiprubart Study

(MENAFN- Investor Ideas) (Investorideas Newswire) a go-to platform for big investing ideas, including biotech stocks issues a news and trading alert for Edesa Biotech, Inc. (Nasdaq:EDSA ), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases.

The stock makes the Nasdaq top gainer list on news today, currently trading at $1.5300, up 0.6310 on over 38 Million shares as of this report. The stock has a morning high of $1.60.

Edesa Biotech announced today positive additional data from a Phase 3 study of paridiprubart.

The results represent a broader, 278-patient population, which includes both previously reported 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients. Across this full population, the company's first-in-class anti-TLR4 antibody demonstrated a statistically significant reduction in 28-day mortality. Treatment benefits were consistent across severity groups and in patients with serious comorbidities.

Key Findings

The primary endpoint was achieved for the full treatment population of 278 randomized subjects. Paridiprubart reduced adjusted 28-day mortality to 24% from 33%, a 27% relative reduction in the risk of death (p<0.001). In addition, subjects receiving paridiprubart demonstrated a higher relative rate of clinical improvement by Day 28. Paridiprubart or placebo were provided in addition to standard of care treatments (SOC).

In an exploratory analysis of a milder population of 174 randomized patients who did not meet the study's IMV-based inclusion criteria, paridiprubart + SOC reduced adjusted 28-day mortality to 15% from 23% (placebo + SOC), a 35% relative reduction in the risk of death (p<0.05).

Edesa also reported that exploratory analyses across a patient population of up to 108 randomized subjects consistently demonstrated reduced adjusted mortality for paridiprubart + SOC vs. placebo + SOC at 28 days in subjects with clinically important comorbidities:

Acute Kidney Injury: 35% relative reduction (35% paridiprubart vs. 53% placebo; p<0.05, n=48) Sepsis: 36% relative reduction (40% paridiprubart vs. 63% placebo; p<0.05, n=41) Pneumonia: 30% relative reduction (35% paridiprubart vs. 49% placebo; p<0.05, n=108)

Overall rates of adverse events, serious adverse events, infections and treatment discontinuations were low and similar between the paridiprubart and placebo groups. The safety profile was consistent with prior clinical exposures, with more than 400 patients now having received paridiprubart.

Based in part on these positive results, Edesa has filed provisional patent applications with the United States Patent and Trademark Office covering the use of paridiprubart in the treatment of sepsis, acute kidney injury and pneumonia. The company's core composition-of-matter patents extend into the 2030s.

Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech, said that the results announced today align with the central role of TLR4 in hyperinflammatory ARDS (Acute Respiratory Distress Syndrome) and demonstrate consistent benefit across high-mortality etiologies.

Full news

Research biotech stocks at Investorideas

/BIS/stock_list

About Investorideas – Where you find the best investing ideas

Investorideas is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

Disclaimer/Disclosure Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: Moredisclaimer anddisclosure info/About/Disclaimer Global investors must adhere to regulations of each country. Please read Investorideas privacy policy: /About/Private_Policy

Learn more about our news, PR and social media, podcast services at Investorideas for AI stocks

/Investors/Services

Learn more about digital advertising and guest posts for AI

/Advertise/

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook

Follow us on YouTube

Sign up for free stock news alerts at Investorideas

/Resources/Newsletter

MENAFN30102026000142011025ID1111892749